Introduction to Lateral Flow Assays

Introduction to Lateral Flow Assays

The webinar introduces lateral flow assays (LFAs), explaining how they work, how they are developed and optimized, and what must be considered when validating them for use. It also presents a case study involving respiratory-disease tests developed for the HoliCare project.

HoliCare context and webinar objectives

HoliCare aims to develop practical, affordable diagnostic tools for respiratory tract infections in sub-Saharan Africa, for settings ranging from rural field clinics to urban hospitals. The project is piloted in Senegal, Uganda, and Ethiopia, and brings together African and European partners. Its work includes point-of-care tests such as LFAs, as well as technologies such as loop-mediated isothermal amplification and microfluidics. The project also addresses infrastructure, digital connectivity, biobanks, and workforce capacity.

The webinar’s objectives are to:

• Explain the basic operation and components of an LFA.
• Describe the role of antibodies in immunoassays.
• Outline assay development, optimization, validation, and troubleshooting.
• Discuss emerging trends and potential future applications.

What lateral flow assays are and how they work

An LFA is a rapid, portable immunoassay used to detect whether an analyte is present in a sample. Results are commonly available within minutes. LFAs are used in clinical diagnostics, infectious-disease testing, food safety, environmental monitoring, and other fields.

A typical test works as follows:

1. Sample application: The sample is added to the sample pad.
2. Flow: Capillary action draws the sample along the strip.
3. Conjugate rehydration: The sample reaches the conjugate pad and releases labelled antibodies, often attached to gold nanoparticles.
4. Target binding: If the target analyte is present, it binds to the labelled antibody.
5. Test-line capture: The complex moves through the nitrocellulose membrane and is captured by an immobilized antibody at the test line, producing a visible signal.
6. Control-line confirmation: Excess conjugate is captured at the control line, indicating that the test has run.
7. Absorption: An absorbent pad draws fluid through the strip and helps maintain flow.

A strip may be a simple exposed “dipstick” or be enclosed in a plastic housing with a sample port and result window.

Main assay formats

• Sandwich assays: The target is bound between a labelled detection antibody and an immobilized capture antibody. This format is suited to larger analytes with multiple binding sites, such as proteins and many antigens.
• Competitive assays: Used especially for small molecules with only one available binding site, such as some drugs, hormones, pesticides, or toxins. Signal intensity is inversely related to analyte concentration: a weaker test signal can indicate more analyte. This interpretation can be counterintuitive, so a reader may help.
• Inhibition assays: Similar in principle to competitive assays, but the competing antigen is immobilized at the test line rather than attached to the conjugate.

Antibodies and early screening

Antibodies are central to LFA performance. Important selection criteria include:

• Affinity: How strongly the antibody binds its target.
• Specificity: Whether it binds the target without reacting with similar molecules.
• Stability: Whether it performs consistently across changes in temperature, pH, and storage time.

Monoclonal antibodies can provide greater consistency than polyclonal antibodies. Recombinant monoclonals can help reduce variability associated with hybridoma-based production. Polyclonals can nevertheless be useful as capture reagents because they recognize multiple sites on an antigen; their disadvantage is the risk of batch-to-batch variation. Reliable suppliers and a consistent supply are important, particularly when moving toward manufacturing.

The presenter described using high-throughput, label-free surface plasmon resonance (SPR) to screen antibodies. The system can assess binding kinetics and help identify antibodies that bind poorly. Epitope binning can show whether antibodies bind the same or different regions of an antigen, helping narrow down potential antibody pairs.

These techniques are useful for early triage, but candidate pairs still need to be tested in the intended assay format: results from one platform do not guarantee performance in another.

LFA design and material selection

Design begins with a clear understanding of the target, intended use, and sample type—for example, blood, saliva, or urine. These factors influence the assay format, buffers, pads, and label.

Important design choices include:

• Label: Gold nanoparticles are common; latex beads, fluorescent labels, and enzymes are alternatives. Selection depends on visibility, stability, and compatibility with the assay and sample.
• Sample pad: Receives the sample, may filter unwanted material, and delivers the sample uniformly. It can be treated with surfactants, buffer salts, or blocking reagents to control wetting, pH, ionic strength, and background.
• Conjugate pad: Stores the labelled reagent in a dry state and releases it when wetted. Material choice, pore structure, pretreatment, and stabilizing sugars or polymers affect release and shelf life.
• Nitrocellulose membrane: The main detection surface, where capture molecules are immobilized. Smaller pores can increase binding area and sensitivity but slow flow; larger pores can speed flow but may reduce binding efficiency. Membrane flow rate and protein-binding properties affect sensitivity and reproducibility.
• Absorbent pad: Draws fluid through the test and absorbs excess sample. It must have enough capacity and suit the sample’s volume and viscosity.
• Backing card and assembly: Supports and aligns the components. Overlaps between components and adhesive compatibility matter for consistent flow and reliable assembly.

Buffers, dispensing methods, drying conditions, and flow rate also require optimization. The team emphasized using dependable material suppliers and checking batch consistency, compatibility, quality, cost, and availability at scale.

Development and optimization workflow

A typical development process involves:

1. Define the analyte, intended use, and sample matrix.
2. Select the assay format and potential labels.
3. Screen antibodies for binding, specificity, and suitable pairing.
4. Test promising pairs directly in lateral flow.
5. Optimize materials, including pads and membrane type, and assess different suppliers and flow properties.
6. Optimize buffers, blocking, stabilization, dispensing, and drying.
7. Balance assay speed against sensitivity and ensure the signal is clear and interpretable.
8. Confirm performance using relevant samples, rather than relying only on clean buffer tests.

Validation and troubleshooting

Validation should establish that the assay meets its design specifications and intended use. Key areas include:

• Sensitivity: Ability to detect low analyte concentrations.
• Specificity: Avoidance of false positives from cross-reactivity.
• Reproducibility: Consistency across operators, environmental conditions, and production batches.
• Robustness: Performance after exposure to conditions such as high humidity or extreme temperatures.
• Stability: Accelerated-aging and storage studies to estimate performance over time.
• Regulatory readiness: Appropriate standards, documentation, technical files, and statistical analysis.

Common problems and suggested responses include:

• Weak or absent signal: Reassess antibody binding and pairing, conjugate condition, and reagent concentrations; check storage conditions.
• High background or nonspecific binding: Reconsider antibody choices, optimize blocking reagents such as BSA or casein, and assess washing or clearing steps.
• Inconsistent flow: Check membrane variability, material quality, component alignment, and manufacturing quality controls.
• Visual interpretation differences: Test readability across operators and lighting conditions; readers can reduce subjectivity.

The Q&A also addressed environmental exposure. The presenter said tests can be assessed through accelerated-aging and excursion studies—for example, testing after exposure to high temperature or humidity—and may be packaged with desiccants. Temperature was highlighted as a particular concern.

Trends and project examples

Emerging developments include multiplex tests that detect multiple analytes on one strip, semi-quantitative or quantitative readings, reader devices, and smartphone-based interpretation. Smartphone integration can quantify signal, guide users, and store or share results, but device and software variation raises validation considerations.

The presenter suggested that hybrid tests combining nucleic-acid amplification with lateral-flow detection may be an important direction. In one example, amplification methods such as LAMP or RPA produce labelled amplicons that can then be detected using an LFA.

A GADx development example illustrated antibody screening for a neglected tropical disease:

• An immunization campaign produced 48 antibodies.
• Binding and epitope-screening methods narrowed the candidates.
• Sixteen antibodies were taken into lateral-flow pairing tests.
• Promising pairs were assessed for signal, background, and sensitivity.
• Materials and assay conditions were optimized before selected candidates proceeded to clinical-sample testing.

For HoliCare, GADx worked on a multiplex test for influenza A, influenza B, and COVID-19, plus a separate RSV test. The multiplex device detects influenza A and B on one line and COVID-19 on another. Both devices were designed for smartphone-app reading and were reported to provide results within 20 minutes. The app is intended to support more objective interpretation, user guidance, and real-time data collection.

Main takeaways

• Antibody selection is pivotal: poor antibodies are likely to result in a poor assay.
• Early screening can save time, but final antibody pairs must be confirmed in the actual LFA format.
• Every component—from sample pad to backing card—can affect performance.
• Material consistency, careful optimization, and testing under realistic conditions are essential.
• Validation should cover sensitivity, specificity, reproducibility, robustness, stability, and usability.
• Readers and smartphone tools can help address subjective visual interpretation, but they also require appropriate validation.

Speakers and sources featured

• Michael Johnson — Senior Scientist at GADx; presenter on LFA design, development, and validation.
• Dr. Anneliese Duvoix (the subtitles also render the name as “Anneliese Dubois” or “Annelies”) — GADx programme manager for the HoliCare project; webinar host and Q&A moderator.
• Webinar participants who asked questions: Constantinos; a participant identified as being from the MASK team; Martin Trotter; Asma Jamali; John Blackabuja; and Negato Negash.
• Organizations and projects discussed: HoliCare and GADx. The HoliCare introduction and closing remarks were delivered by the webinar host.